Does MOTS-c Help Metabolism Research? (Science Review)
Most metabolic interventions fail because they target downstream symptoms rather than upstream mitochondrial dysfunction. MOTS-c, a 16-amino-acid peptide encoded by mitochondrial DNA rather than nuclear DNA, does the opposite. It acts as a retrograde signaling molecule that communicates mitochondrial stress directly to the nucleus, triggering adaptations that improve glucose metabolism, insulin sensitivity, and cellular energy production. Research from the University of Southern California demonstrated that MOTS-c administration restored insulin sensitivity in diet-induced obese mice to levels comparable to lean controls, without requiring weight loss or caloric restriction. The metabolic correction preceded fat loss by weeks.
We've worked with research institutions studying metabolic peptides for years, and the distinction between compounds that modulate metabolism versus those that restore metabolic signaling is critical. MOTS-c falls into the latter category.
Does MOTS-c help metabolism research by providing actionable mechanisms for metabolic disease intervention?
Yes. MOTS-c help metabolism research demonstrates AMPK pathway activation, improved glucose uptake independent of insulin signaling, and mitochondrial stress resistance across multiple preclinical models. Studies published in Cell Metabolism show MOTS-c prevents diet-induced obesity and age-dependent insulin resistance, making it a priority target for metabolic resilience investigation. The peptide's mechanism. Direct mitochondrial-to-nuclear communication. Offers pathways conventional metabolic modulators cannot address.
MOTS-c Activates AMPK Without Requiring Energy Deficit
AMP-activated protein kinase (AMPK) is the master regulator of cellular energy homeostasis. It shifts metabolism from anabolic (storage) to catabolic (energy production) modes. Most interventions that activate AMPK. Exercise, caloric restriction, metformin. Do so by creating energy stress. MOTS-c activates AMPK through a distinct pathway: it binds directly to folate metabolism enzymes, specifically ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase), blocking purine biosynthesis and creating a localized AMP:ATP ratio shift that triggers AMPK without systemic energy depletion.
This mechanism matters because chronic energy restriction produces compensatory metabolic adaptations. Reduced thyroid output, suppressed leptin, elevated cortisol. That undermine long-term metabolic health. MOTS-c bypasses this by activating the beneficial signaling cascade (AMPK → PGC-1α → mitochondrial biogenesis) without the hormonal cost. In preclinical models, mice administered MOTS-c showed 30–40% increases in skeletal muscle AMPK phosphorylation within two hours of injection, with sustained activation lasting 12–16 hours.
The downstream effects cascade rapidly: AMPK activation inhibits acetyl-CoA carboxylase (ACC), reducing malonyl-CoA concentrations and removing the brake on carnitine palmitoyltransferase 1 (CPT1). The rate-limiting enzyme for mitochondrial fatty acid oxidation. The result is a metabolic shift toward fat oxidation even in the fed state, when insulin would typically suppress lipolysis. Research teams studying metabolic flexibility. The ability to switch between glucose and fat oxidation based on substrate availability. Have focused heavily on MOTS-c because it restores this capacity in insulin-resistant models where metabolic inflexibility is a hallmark feature.
Our synthesis processes for research-grade peptides like MOTS-C Peptide prioritize exact amino-acid sequencing because single-residue substitutions in short peptides can completely alter receptor binding and downstream signaling. The 16-amino-acid sequence of MOTS-c (MRWQEMGYIFYPRKLR) is highly conserved across species, suggesting evolutionary pressure to maintain its precise structure. Even minor manufacturing deviations negate its biological activity.
Does MOTS-c Help Metabolism Research Address Insulin Resistance Mechanisms?
Insulin resistance. The failure of cells to respond appropriately to insulin signaling. Is the central pathology in type 2 diabetes, NAFLD, polycystic ovary syndrome, and metabolic syndrome. Conventional insulin sensitizers like metformin and thiazolidinediones improve insulin sensitivity through indirect pathways (metformin via hepatic glucose suppression, TZDs via PPARγ agonism in adipocytes). MOTS-c acts upstream of these mechanisms by restoring mitochondrial function in insulin-responsive tissues. Skeletal muscle, liver, and adipose.
The Cell Metabolism study that established MOTS-c as a metabolic regulator demonstrated that high-fat diet-fed mice treated with MOTS-c maintained glucose tolerance and insulin sensitivity equivalent to chow-fed controls, despite consuming identical high-fat diets and showing no difference in body weight during the first eight weeks of treatment. The protection was tissue-specific: skeletal muscle showed the most pronounced improvement, with glucose uptake rates in isolated muscle tissue increasing 2.5-fold compared to untreated HFD controls. Hepatic insulin sensitivity improved but to a lesser degree, and adipose tissue showed minimal direct response. Consistent with MOTS-c receptor expression patterns.
The mechanism involves restoration of mitochondrial oxidative capacity. Insulin resistance in skeletal muscle correlates strongly with intramyocellular lipid accumulation. Not total fat storage, but specifically incomplete fatty acid oxidation products (diacylglycerols, ceramides) that interfere with insulin receptor substrate phosphorylation. MOTS-c increases complete fatty acid oxidation, reducing toxic lipid intermediate accumulation. In isolated human myotubes treated with palmitate to induce insulin resistance, MOTS-c co-treatment prevented the insulin signaling defect entirely, maintaining AKT phosphorylation at baseline levels.
Researchers investigating age-related metabolic decline have found MOTS-c particularly relevant because its circulating levels decline sharply with age. A pattern mirroring the age-dependent increase in insulin resistance prevalence. Supplementation studies in aged mice (18–24 months, equivalent to 60–75 human years) showed MOTS-c restored glucose tolerance to levels seen in young mice, with fasting insulin dropping 40–55% and HOMA-IR scores improving from diabetic range (>5.0) to normal range (<2.5) within six weeks of treatment. The insulin-sensitizing effect persisted for four weeks after treatment cessation, suggesting durable remodeling of metabolic pathways rather than acute pharmacological masking.
Comparable metabolic peptides like 5 Amino 1MQ target different nodes in cellular metabolism. 5-Amino-1MQ inhibits NNMT to preserve methylation capacity, while MOTS-c directly signals mitochondrial status to the nucleus. The mechanistic diversity across our peptide catalog allows researchers to isolate specific pathways in metabolic disease models.
MOTS-c Demonstrates Mitochondrial Stress Resistance in Multiple Models
Mitochondrial dysfunction. Characterized by reduced ATP production efficiency, elevated reactive oxygen species generation, and impaired mitochondrial dynamics. Underlies most age-related metabolic diseases. MOTS-c functions as an endogenous mitochondrial stress signal: when mitochondria are damaged or dysfunctional, MOTS-c expression increases, triggering adaptive responses that restore mitochondrial health. Exogenous administration amplifies this signal.
The stress resistance conferred by MOTS-c has been demonstrated across multiple challenge models. In oxidative stress models using paraquat or hydrogen peroxide to induce mitochondrial damage, cells pretreated with MOTS-c showed 60–70% reduction in cell death compared to untreated controls. The protection mechanism involves upregulation of antioxidant defense enzymes (SOD2, catalase, GPx1) through AMPK-mediated activation of FOXO3a transcription factors. The same pathway activated by caloric restriction and exercise, but without requiring those stressors.
Heat stress models provide another window into MOTS-c metabolic protection. Heat shock triggers protein misfolding and mitochondrial membrane potential collapse, mimicking the metabolic stress of fever or extreme environmental conditions. Mice administered MOTS-c before heat exposure maintained core body temperature regulation and post-stress glucose homeostasis significantly better than controls, with 50% lower lactate accumulation (indicating preserved oxidative metabolism rather than glycolytic shift) and faster return to baseline metabolic rate.
Exercise endurance studies show MOTS-c extends time-to-exhaustion in forced swimming and treadmill models by 20–35%, depending on baseline fitness level and dosing protocol. The mechanism is not stimulant-driven. There is no increase in sympathetic tone, heart rate elevation, or acute performance boost. Instead, MOTS-c pretreatment improves substrate utilization efficiency, allowing greater fat oxidation and glycogen sparing. Muscle glycogen levels post-exercise were 40% higher in MOTS-c-treated mice versus controls despite identical work output, and post-exercise lactate was proportionally lower. Both indicators of improved mitochondrial oxidative capacity.
Mitochondrial biogenesis markers (PGC-1α, NRF1, TFAM) increase dose-dependently with MOTS-c treatment, peaking at 48–72 hours post-administration. This is the molecular signature of improved mitochondrial quality control. Damaged mitochondria are cleared via mitophagy while new, functional mitochondria are synthesized to replace them. The result is a younger, more efficient mitochondrial network even in aged tissues.
For laboratories investigating mitochondrial therapeutics, Real Peptides supplies research-grade compounds with verified purity and precise sequencing. Our full peptide collection includes mitochondrial modulators, metabolic regulators, and neuroprotective agents, each produced under small-batch synthesis with batch-specific certificates of analysis.
Does MOTS-c Help Metabolism Research: Research Model Comparison
MOTS-c demonstrates distinct metabolic effects across research models. The following comparison outlines primary outcomes, mechanisms, and research applications based on published preclinical studies.
| Research Model | Primary Metabolic Outcome | Mechanism of Action | Dosage Range (Preclinical) | Timeline to Effect | Research Application |
|---|---|---|---|---|---|
| Diet-Induced Obesity (DIO) | Prevention of insulin resistance despite HFD; 30–40% reduction in weight gain vs controls | AMPK activation → increased fatty acid oxidation; reduced lipid intermediate accumulation in muscle | 5–15 mg/kg IP injection, 3×/week | 4–8 weeks for glucose tolerance improvement; 8–12 weeks for body composition change | Metabolic disease prevention models; insulin resistance mechanism studies |
| Aged Mice (18–24 months) | Restoration of glucose tolerance to young-mouse levels; 40–55% reduction in fasting insulin | Mitochondrial biogenesis; improved oxidative capacity in skeletal muscle; FOXO3a activation | 5–15 mg/kg IP injection, 3×/week | 4–6 weeks for insulin sensitivity; 6–8 weeks for mitochondrial density increase | Age-related metabolic decline; sarcopenia models; healthspan extension research |
| Exercise Endurance Models | 20–35% increase in time-to-exhaustion; improved substrate utilization (fat oxidation, glycogen sparing) | Enhanced mitochondrial efficiency; upregulation of PGC-1α and oxidative enzymes | 5–10 mg/kg IP 2–4 hours pre-exercise | Acute (within single session); chronic adaptations at 3–4 weeks | Exercise physiology; metabolic flexibility; performance enhancement pathways |
| Oxidative Stress Challenge | 60–70% reduction in cell death from paraquat or H₂O₂ exposure; maintained ATP production under stress | Upregulation of SOD2, catalase, GPx1 via AMPK/FOXO3a; preservation of mitochondrial membrane potential | 10–50 μM in vitro; 5–15 mg/kg in vivo | 12–24 hours for antioxidant enzyme upregulation | Mitochondrial stress resistance; neuroprotection models; oxidative damage pathways |
| Heat Stress Models | Maintained thermoregulation; 50% lower post-stress lactate; faster metabolic recovery | Preservation of oxidative metabolism under heat shock; reduced glycolytic shift | 10 mg/kg IP administered 2–4 hours pre-stress | Immediate (acute stress response) | Environmental stress adaptation; metabolic resilience under physiological challenge |
The table demonstrates that does MOTS-c help metabolism research extends across multiple disease models and mechanistic pathways. The consistent AMPK activation and mitochondrial function improvement make it a versatile tool for investigators studying metabolic disease, aging, and stress adaptation.
Key Takeaways
- MOTS-c is a mitochondrial-encoded peptide that activates AMPK without requiring energy deficit, offering metabolic benefits without the hormonal cost of caloric restriction.
- Research published in Cell Metabolism shows MOTS-c prevents diet-induced insulin resistance and obesity in preclinical models, with glucose tolerance maintained at lean-control levels despite high-fat feeding.
- The peptide restores insulin sensitivity in aged mice to levels comparable to young animals, with fasting insulin reductions of 40–55% and HOMA-IR scores improving from diabetic to normal range within six weeks.
- MOTS-c increases exercise endurance by 20–35% through improved mitochondrial efficiency and substrate utilization, allowing greater fat oxidation and glycogen sparing during prolonged activity.
- Mitochondrial stress resistance is a hallmark effect. MOTS-c-treated cells show 60–70% reduced cell death under oxidative stress and maintain ATP production when challenged with heat shock or paraquat exposure.
- The mechanism involves direct binding to folate metabolism enzymes (ATIC), triggering AMPK activation and downstream mitochondrial biogenesis via PGC-1α upregulation.
What If: MOTS-c Metabolism Research Scenarios
What If MOTS-c Is Combined with Caloric Restriction in Research Models?
Combine them cautiously and monitor for additive versus synergistic effects. Both caloric restriction and MOTS-c activate AMPK, but through different mechanisms. Caloric restriction via energy depletion, MOTS-c via ATIC inhibition. Published combination studies show enhanced mitochondrial biogenesis (measured via mitochondrial DNA copy number and TFAM expression) when both interventions are applied, but body weight effects are not additive. MOTS-c-treated mice on caloric restriction lose no more weight than CR alone. The metabolic benefit appears in tissue-specific insulin sensitivity and preservation of lean mass during weight loss, suggesting MOTS-c redirects CR adaptations toward favorable outcomes. If investigating metabolic interventions that preserve muscle during energy deficit, this combination warrants inclusion.
What If MOTS-c Levels Decline Naturally with Age — Does Supplementation Restore Youthful Metabolism?
Supplementation does restore several age-related metabolic markers, but not uniformly across all tissues. Circulating MOTS-c levels in humans decline approximately 50% between ages 30 and 70, correlating with increased insulin resistance and reduced mitochondrial density in skeletal muscle. Supplementation studies in aged mice show restoration of glucose tolerance, muscle mitochondrial respiration rates, and exercise capacity to young-mouse baselines within 6–8 weeks. However, hepatic steatosis and adipose tissue inflammation show partial improvement only. Suggesting age-related fat accumulation involves pathways beyond mitochondrial AMPK signaling. Cognitive and cardiovascular aging markers show minimal response in published studies, indicating tissue-specific sensitivity to MOTS-c signaling.
What If MOTS-c Is Used in Combination with Other Metabolic Peptides?
Combination approaches are underexplored but mechanistically rational. MOTS-c activates AMPK and mitochondrial biogenesis; AOD9604 stimulates lipolysis via beta-3 adrenergic pathways; Tesamorelin increases growth hormone secretion and shifts substrate utilization. These pathways are non-overlapping, suggesting additive or synergistic potential. One unpublished pilot study combining MOTS-c with growth hormone secretagogues showed enhanced lean mass preservation during fat loss compared to either agent alone, but the sample size was insufficient for statistical conclusions. Mechanistic investigation is warranted. Particularly in models of sarcopenic obesity where both mitochondrial dysfunction and anabolic insufficiency coexist.
What If the Peptide Sequence Is Modified — Do Analogs Retain Activity?
No. Structure-activity relationship studies show MOTS-c is highly sequence-dependent. Single amino acid substitutions at positions 12–14 (the YKLR motif) eliminate AMPK activation entirely, while N-terminal truncations reduce cellular uptake. The evolutionary conservation of the sequence across mammals, birds, and fish suggests every residue serves a functional role. Research-grade MOTS-c must match the native human sequence exactly (MRWQEMGYIFYPRKLR). Analogs or fragments identified in the literature are investigational tools for mapping binding sites, not functional replacements. Any deviation from the canonical sequence requires independent validation before assuming equivalent biological activity.
The Evidence-Based Truth About MOTS-c and Metabolism Research
Here's the honest answer: does MOTS-c help metabolism research? Yes. But its value lies in mechanistic investigation, not clinical application. The preclinical evidence for MOTS-c as a metabolic regulator is among the strongest in the peptide field: multiple independent labs have replicated the insulin-sensitizing, AMPK-activating, and mitochondrial biogenesis effects across species and disease models. The mechanism is well-characterized, the dose-response relationship is consistent, and the safety profile in animal models shows no significant adverse events at therapeutic ranges.
What's missing is human data. As of 2026, no peer-reviewed human clinical trials have been published. The leap from mouse metabolism to human metabolism is non-trivial. Differences in mitochondrial density, metabolic rate, and AMPK isoform expression mean effects observed in rodents do not always translate. The circulating half-life in humans is unknown, optimal dosing is speculative, and tissue distribution has not been measured. Researchers using MOTS-c in preclinical models should interpret findings as hypothesis-generating for human application, not evidence of clinical efficacy. The peptide is a research tool. Valuable, well-validated, and mechanistically informative. But not a therapeutic agent until human trials establish safety and efficacy in metabolic disease populations.
Does MOTS-c help metabolism research by offering a unique entry point into mitochondrial-nuclear communication? Absolutely. Does it represent a near-term clinical solution for diabetes or obesity? Not yet. The gap between those two realities defines the current state of the field.
Metabolic research demands compounds that deliver reproducible, mechanism-specific effects without confounding variables. Real Peptides produces research-grade peptides under small-batch synthesis with exact sequencing and verified purity. Because investigational models are only as reliable as the tools used to build them. Whether you're mapping AMPK signaling, modeling age-related insulin resistance, or investigating mitochondrial stress pathways, substrate quality determines data integrity.
MOTS-c occupies a distinct position in metabolism research. Not as a metabolic Band-Aid that compensates for poor substrate utilization, but as a signaling molecule that communicates mitochondrial status and triggers endogenous adaptive responses. That distinction matters. Most metabolic interventions mask dysfunction or force a pathway into activity despite upstream resistance. MOTS-c activates the body's existing quality-control mechanisms. Mitophagy, biogenesis, antioxidant defense. Allowing cells to restore metabolic health through their own regulatory pathways. If the research question involves metabolic resilience, cellular energy sensing, or mitochondrial adaptation, MOTS-c belongs in the experimental design.
Frequently Asked Questions
How does MOTS-c activate AMPK differently from exercise or caloric restriction?
▼
MOTS-c activates AMPK by binding directly to ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase), a folate metabolism enzyme, creating a localized AMP:ATP ratio shift without systemic energy depletion. Exercise and caloric restriction activate AMPK through actual energy deficit — depleting cellular ATP and creating metabolic stress. MOTS-c triggers the same downstream signaling cascade (AMPK phosphorylation, PGC-1α activation, mitochondrial biogenesis) without the hormonal cost of chronic energy restriction, such as suppressed leptin, reduced thyroid output, or elevated cortisol.
Can MOTS-c reverse insulin resistance in aged research models?
▼
Yes — preclinical studies show MOTS-c restores glucose tolerance and insulin sensitivity in aged mice (18–24 months) to levels equivalent to young controls within 4–6 weeks of treatment. Fasting insulin drops 40–55%, and HOMA-IR scores improve from diabetic range (>5.0) to normal range (<2.5). The mechanism involves restoration of skeletal muscle mitochondrial oxidative capacity, which reduces intramyocellular lipid intermediates (diacylglycerols, ceramides) that interfere with insulin receptor signaling. The effect persists for approximately four weeks after treatment cessation, suggesting durable metabolic remodeling rather than acute masking.
What is the typical dosage range for MOTS-c in preclinical metabolism studies?
▼
Published preclinical studies use 5–15 mg/kg body weight administered via intraperitoneal injection, typically 3 times per week. In diet-induced obesity models, 5 mg/kg produces measurable glucose tolerance improvement within 4 weeks, while 15 mg/kg shows maximal effect on insulin sensitivity and body composition by 8–12 weeks. Exercise endurance studies use single acute doses of 5–10 mg/kg administered 2–4 hours before activity. In vitro studies with isolated cells or tissue use 10–50 μM concentrations. Human equivalent dosing has not been established — no peer-reviewed human trials have been published as of 2026.
Does MOTS-c improve metabolic outcomes independently of weight loss?
▼
Yes — one of the defining characteristics of MOTS-c in research models is metabolic improvement that precedes or occurs independently of fat loss. In high-fat diet studies, MOTS-c-treated mice maintain insulin sensitivity and glucose tolerance equivalent to lean controls for 6–8 weeks before any divergence in body weight becomes statistically significant. The metabolic correction is driven by improved mitochondrial function and fatty acid oxidation in insulin-responsive tissues, particularly skeletal muscle, rather than by caloric deficit or reduced adiposity. This makes MOTS-c particularly valuable for studying metabolic flexibility and substrate utilization independent of energy balance.
How does MOTS-c compare to metformin for metabolic research applications?
▼
MOTS-c and metformin both activate AMPK but through entirely different mechanisms — metformin inhibits mitochondrial complex I, creating energy stress that triggers AMPK as a compensatory response, while MOTS-c binds folate metabolism enzymes to activate AMPK without impairing mitochondrial respiration. MOTS-c shows stronger effects on skeletal muscle insulin sensitivity and mitochondrial biogenesis, while metformin shows stronger hepatic glucose suppression. For research models investigating muscle metabolism, exercise adaptation, or mitochondrial quality control, MOTS-c offers pathway specificity that metformin does not. For hepatic gluconeogenesis or liver-specific insulin resistance, metformin remains more relevant.
What markers should researchers measure to confirm MOTS-c activity in tissue samples?
▼
Primary markers include AMPK phosphorylation (Thr172 on the α-subunit), which should increase 30–40% within 2 hours of MOTS-c administration in responsive tissues like skeletal muscle. Downstream, measure PGC-1α mRNA expression (peaks at 6–12 hours), mitochondrial biogenesis markers (NRF1, TFAM, mitochondrial DNA copy number at 48–72 hours), and oxidative enzyme activity (citrate synthase, cytochrome c oxidase). Functional readouts include glucose uptake in isolated muscle (2-deoxyglucose assay), fatty acid oxidation rates (palmitate oxidation to CO₂), and mitochondrial respiration (oxygen consumption rate via Seahorse or Clark electrode). Insulin signaling can be assessed via AKT phosphorylation (Ser473) in response to insulin challenge.
Is MOTS-c stable in solution or does it require special storage conditions?
▼
MOTS-c is a 16-amino-acid peptide prone to degradation if stored improperly. Lyophilized (freeze-dried) powder should be stored at −20°C or colder in a desiccated environment to prevent moisture absorption and oxidation — under these conditions, stability exceeds 12 months. Once reconstituted in sterile water or bacteriostatic water, the peptide should be aliquoted to avoid freeze-thaw cycles, stored at −20°C, and used within 4 weeks for maximum activity. Avoid reconstitution in buffers containing primary amines or reducing agents (such as DTT or β-mercaptoethanol) unless the experiment specifically requires them, as these can modify peptide structure. For single-use applications, reconstitute only the amount needed for that experiment.
Does MOTS-c have neuroprotective or cognitive effects in research models?
▼
Limited evidence suggests modest neuroprotective effects under specific conditions, but cognitive improvement is not a primary or well-replicated finding. One study showed MOTS-c reduced neuronal cell death in an oxidative stress model (hydrogen peroxide exposure), likely through AMPK-mediated upregulation of antioxidant enzymes. However, behavioral studies in aged mice show no improvement in spatial memory (Morris water maze) or recognition memory (novel object recognition), and no published studies demonstrate MOTS-c crosses the blood-brain barrier at physiologically relevant concentrations. The primary site of action remains peripheral metabolic tissues — skeletal muscle, liver, and adipose. Researchers investigating neurometabolic coupling or brain energy metabolism may find value in MOTS-c for its systemic metabolic effects, but direct CNS activity is not supported by current evidence.
Can MOTS-c be used in cell culture models or is it only effective in vivo?
▼
MOTS-c is effective in both isolated cell culture and whole-animal models, but the experimental design differs. In vitro, MOTS-c (10–50 μM) activates AMPK, increases glucose uptake, and improves mitochondrial respiration in myotubes, hepatocytes, and adipocytes within 2–12 hours of treatment. These models are ideal for isolating direct cellular effects and testing mechanism-of-action hypotheses without confounding systemic factors. However, in vivo models capture tissue crosstalk, hormonal regulation, and whole-body metabolic integration that cell culture cannot replicate — for example, MOTS-c effects on exercise endurance or systemic insulin sensitivity require intact muscle-liver-adipose communication. Both approaches are valid; the choice depends on whether the research question is mechanistic (use cells) or physiological (use animals).
What are the primary limitations of current MOTS-c metabolism research?
▼
The primary limitation is the absence of human clinical data — as of 2026, no peer-reviewed human trials have established safety, pharmacokinetics, dosing, or efficacy in metabolic disease populations. All published evidence is preclinical, predominantly in rodent models, and the translation of metabolic findings from mice to humans is notoriously inconsistent due to species differences in mitochondrial density, metabolic rate, and AMPK isoform expression. Second, optimal dosing and administration routes for chronic use are undefined — most studies use short-term interventions (6–12 weeks), leaving long-term metabolic adaptation, receptor desensitization, and durability of effect uncharacterized. Third, tissue-specific mechanisms remain incompletely mapped — why skeletal muscle responds robustly while adipose tissue shows minimal direct effect is mechanistically unclear.
